Biosimilars have the potential to reduce health care costs and expand patient access, but economic and policy barriers affect ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

Sarfaraz K. Niazi, PhD, argues that regulatory agencies should eliminate redundant clinical efficacy testing for biosimilars, ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

January started the year off strong, with several business updates, long-term clinical trial results on multiple biosimilars, ...

The Top 5 Biosimilar Articles for the Week of December 2 ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

Number 1: In 2024, the FDA approved 19 biosimilars across various therapeutic areas, including the first biosimilars for ...